Pfizer Inc.
Rank #310ValuePFE · NYSE · Healthcare
Pfizer Inc. (PFE) — Rank #310 by gross profitability (GP/assets 0.23) · ROE 9.1% · Piotroski F-Score 5 / 9.
As-of 2026-09-15 · CIK 0000078003 · all metrics point-in-time as of the filing date.
About
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally.
Show moreShow less
It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc.
was founded in 1849 and is headquartered in New York, New York.
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
- State
- DE
- Filer Category
- Large accelerated filer
- Fiscal Year End
- December 31
- Website
- pfizer.com
Financials
Each fiscal year is read as-of that year’s own 10-K filing, so nothing restated after the fact leaks backwards. Line items this filer never tagged are omitted. Hover or tap a badge for the diagnostic behind it.
| Fiscal year end | 2025-12-31filed 2026-02-26 | 2024-12-31filed 2025-02-27 | 2023-12-31filed 2024-02-22 | 2022-12-31filed 2023-02-23 |
|---|---|---|---|---|
| Operating | ||||
| Depreciation & amortization | 6,592.0 | 7,013.0 | 6,290.0 | 5,064.0 |
| Stock-based compensation | 799.0 | 877.0 | 525.0 | 872.0 |
| Change in receivables | 263.0 | 109.0 | (347.0) | (261.0) |
| Change in inventory | (561.0) | 854.0 | 1,169.0 | (592.0) |
| Operating cash flow | 11,704.0 | 12,744.0 | 8,700.0 | 29,267.0 |
| Investing | ||||
| Capital expenditures | 2,629.0 | 2,909.0 | 3,907.0 | 3,236.0 |
| Acquisitions, net of cash | 6,927.0 | 0.0 | 43,430.0 | 22,997.0 |
| Investing cash flow | (1,351.0) | 2,652.0 | (32,278.0) | (15,783.0) |
| Financing | ||||
| Debt issued | 9,678.0 | 0.0 | 30,831.0 | 0.0 |
| Debt repaid | 6,757.0 | 2,250.0 | 2,569.0 | 3,298.0 |
| Share repurchases | — | 0.0 | 0.0 | 2,000.0 |
| Financing cash flow | (10,304.0) | (17,140.0) | 26,066.0 | (14,834.0) |
| Summary | ||||
| Free cash flow | 9,075.0 | 9,835.0 | 4,793.0 | 26,031.0 |
Figures are as originally filed with the SEC (point-in-time), not restated, so they can differ slightly from sites that show later-restated numbers. Why point-in-time?